Table 1.
Variables | |
---|---|
N | 1,169 |
Age (years) | 62.5 (11.2) |
Male (%) | 59.3 |
Private health insurance coverage (%) | 12.9 |
Diabetologist care (%) | 22.7 |
Dapagliflozin therapy (%) | |
Monotherapy | 10.9 |
Dapagliflozin + metformin | 37.1 |
Dapagliflozin + insulin (±metformin) | 33.5 |
Dapagliflozin + DPP-4i (±metformin) | 9.7 |
Other combinations | 8.9 |
Comorbidity (%) | |
Macrovascular complications | 47.1 |
Microvascular complications | 22.8 |
Hypertension | 78.8 |
Hyperlipidemia | 62.0 |
Notes: Data are mean (SD) or proportions (%) DPP-4i. Macrovascular complications include coronary heart disease, myocardial infarction, peripheral vascular disease, and stroke. Microvascular complications include retinopathy, nephropathy, and neuropathy.
Abbreviations: DPP-4i, dipeptidyl peptidase-4 inhibitor; SD, standard deviation.